It’s normal to have lots of questions when you start a new prescription medication. Whether you can drink alcohol might be at ...
People with a high body weight living in England can now access subsidised weight-loss drugs to treat their obesity.
Drug compounders aren’t ready to give up their ability to produce off-brand versions of Novo Nordisk’s weight-loss drug ...
Last week, the US Food and Drug Administration (FDA) announced the end of a years-long shortage of semaglutide injection products — a ...
The popular medications may still suffer from local shortages, but FDA is confident that the national supply will remain ...
New diabetes medications are pressuring Medicare Part D financially as they drive up prescription drug costs amid rising ...
Hims & Hers stock drops 26% as FDA resolves semaglutide shortage, threatening GLP-1 revenue. Click here to find out why HIMS ...
Lars Fruergaard Jørgensen might not be a household name, but his company’s drug Ozempic is. And its success has thrust him — ...
Despite the continued success of GLP-1 drugs Ozempic and Wegovy, Novo Nordisk CEO Lars Fruergaard Jørgensen took a slight pay cut in 2024. He received 57.1 million Danish kroner (DKK) – $8 million – ...
The United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA) reports an increase in deaths linked to ...
Risk of suicidality wasn't higher for type 2 diabetes patients starting on GLP-1 receptor agonists than for those on two other popular classes of diabetes drugs, a U.K. cohort study found. In fully ...
Lars Fruergaard Jørgensen is a CEO who didn't want to be CEO but under his tenure Novo Nordisk, which makes Ozempic, has ...